Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBsAg positive and anti-HBs negative more than 6 months~* YMDD mutation (+)during lamivudine therapy~* Serum ALT more than two times upper normal value~Exclusion Criteria:~* HAV IgM Ab + and/or HCV Ab+ and/or HDV Ab and/or HIV Av+~* The sign of decompensated liver disease~* Pregnant or lactating woman~* The history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease~* Hemoglobin less than 8 g/dL (male), 7.5g/dL (female) or neutrophil count less than 1500/mm3 or platelet count less than 50,000/mm3~* Serum creatinine more than 1.5 times upper normal limit value~* The sign of malignancy or suggestive of malignancy or the history of malignancy, the recurrence rate within 2 years of which is more than 20%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamivudine plus adefovir (Type: ACTIVE_COMPARATOR): None
- Clevudine plus adefovir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).